Sonablate Corp.

Sonablate Corp. is a leader in high-intensity focused ultrasound (HIFU) technology, specializing in the treatment of prostate diseases, particularly prostate cancer. Founded in 2004 and based in Charlotte, North Carolina, the company develops advanced surgical ablation systems that use focused ultrasound energy to target and destroy malignant prostate tissue while preserving healthy tissue. The flagship Sonablate HIFU system is approved in over 50 countries and has treated more than 40,000 patients worldwide. It offers a robotic, focal therapy approach that reduces side effects associated with traditional prostate treatments. Sonablate's product portfolio includes the Sonablate 450, Sonablate 500, and Sonatherm, each designed for minimally invasive prostate cancer treatment. The company also provides clinical training, repair, and ongoing support for healthcare providers. Sonablate collaborates with leading academic institutions and has been recognized for its innovation in non-invasive focused ultrasound technologies.

• Employees71
• Founded2004
• Annual Revenue$35000000
• Total Funding$3377000